Polydatin possesses notable anti-osteoporotic activity via regulation of OPG, RANKL and beta-catenin

摘要

This study was designed to investigate the anti-osteoporotic activity of polydatin and its possible underlying mechanism. Osteoporosis was induced in mice by ovariectomy (OVX) and the mice were divided into 5 groups: An OVX only group, polydatin groups (10, 20 and 40 mg/kg) and a sham group (n=10/group). After 12 weeks of treatment, body weight, uterine index and the dry weight of thigh-bones were recorded. In addition, the serum calcium, serum phosphorus, alkaline phosphatase (ALP) and osteoprotegerin (OPG) levels were also determined. Western blot analysis was then conducted to investigate the possible mechanism underlying the effect of polydatin via determining the expression of OPG, receptor activators of nuclear factor-kappa B ligand (RANKL) and beta-catenin in the ST2 cell line. The results indicated that intraperitoneal injection of polydatin (10, 20 and 40 mg/kg/day) decreased body weight, and increased uterine index and dry weights of thigh-bones of ovariectomized mice (P0.05), and polydatin also significantly increased the serum calcium, phosphorus, ALP and OPG of ovariectomized mice (P0.05). Results of western blot analysis showed that polydatin upregulated the ratio of OPG/RANKL (P0.05) and beta-catenin protein in ST2 cells. In conclusion, the results demonstrated that polydatin exhibits anti-osteoporotic activity via regulating osteoprotegerin, RANKL and beta-catenin.